No, neuromyelitis optica spectrum disorder (NMOSD) does not cause sinusoidal obstruction syndrome.
NMOSD and sinusoidal obstruction syndrome (SOS) are completely unrelated conditions with distinct pathophysiologies and no established causal relationship.
Understanding the Distinct Pathologies
Sinusoidal Obstruction Syndrome
According to the EASL Clinical Practice Guidelines, SOS is a hepatic vascular disease characterized by sinusoidal endothelial cell injury and detachment, leading to hepatic outflow obstruction 1. The established causes are:
- Myeloablative regimens in hematopoietic stem cell transplantation (HSCT)
- Chemotherapeutic agents (cyclophosphamide, busulfan, oxaliplatin, gemtuzumab-ozogamicin, etc.)
- Immunosuppressants (azathioprine, 6-mercaptopurine, 6-thioguanine)
- Radiation therapy (total body or hepatic irradiation)
- Pyrrolizidine alkaloids and other hepatotoxins
- ABO-incompatible platelet transfusions 1
Neuromyelitis Optica Spectrum Disorder
NMOSD is an autoimmune inflammatory disease of the central nervous system, predominantly targeting optic nerves and spinal cord through aquaporin-4 antibody-mediated astrocytopathy 2, 3, 4. The pathology involves:
- Autoantibodies against aquaporin-4 water channels on astrocytes
- Complement-dependent and antibody-dependent cytotoxicity
- Demyelination and neuronal injury
- No hepatic or vascular endothelial involvement 2, 4, 5
Critical Clinical Distinction
The only documented connection between these conditions exists in one exceptional pediatric case report where seronegative NMOSD developed after haploidentical HSCT for acute myeloid leukemia 6. However, this represents:
- NMOSD as a complication of HSCT (likely immune-mediated post-transplant phenomenon)
- Not NMOSD causing SOS
- The patient had undergone myeloablative conditioning (the actual SOS risk factor)
- NMOSD emerged on day +145 post-transplant alongside chronic GVHD 6
Clinical Implications
If a patient presents with both conditions:
- Consider HSCT as the common underlying exposure causing both complications independently
- Evaluate for myeloablative chemotherapy or immunosuppressant exposure (the true SOS causes)
- Do not attribute SOS to NMOSD itself
- Manage each condition according to its specific treatment protocols 1, 4, 7
Common pitfall to avoid: Confusing temporal association with causation. The presence of both conditions in a post-HSCT patient reflects shared exposure to causative agents (chemotherapy, immunosuppression), not a pathophysiologic link between NMOSD and SOS.